Triptorelin

Triptorelin is a synthetic decapeptide modeled on the body's own gonadotropin-releasing hormone (GnRH). Unlike many compounds in the research space, triptorelin is an actually approved drug: under brand names like Decapeptyl or Trelstar it has been used in medicine for decades, including in prostate cancer, endometriosis and precocious puberty. So there is plenty of human data here - a rare and welcome starting point.

The crucial thing about triptorelin is that the same substance does two completely opposite things depending on how it is used. A single dose acts as a short push on the hormone axis. Continuous, ongoing dosing (depot) does the exact opposite after a few weeks: it powers the axis down. Confuse the two and you misunderstand the substance entirely.

This information is provided solely for research and educational purposes. No medical recommendations.

Triptorelin binds to the GnRH receptors in the pituitary gland - the same receptors that the body's own pulsatile GnRH normally drives. What happens next depends entirely on the timing pattern of dosing:

• First dose (flare): The pituitary is stimulated and releases a burst of LH and FSH. That drives the gonads to produce more testosterone or estradiol. This acute rise is well documented in studies and is even used deliberately in reproductive medicine to trigger an LH surge.
• Continuous dosing (suppression): With continuous, non-pulsatile occupation of the receptors, the pituitary responds with downregulation and desensitization. After typically 2 to 4 weeks, LH and FSH collapse and gonadal hormone production drops to the floor. This exact effect is used in prostate cancer, where the goal is to push testosterone down to castration levels.

That is the core: a pulse pushes, continuous bombardment switches off. In prostate cancer use, the initial flare phase is actually a known problem because the short testosterone rise can temporarily worsen the disease (so-called tumor flare) - the FDA label warns about this explicitly.

Before you start, have everything ready:

• The triptorelin vial with the lyophilized powder
• Bacteriostatic water to reconstitute it
• U-100 insulin syringes for use
• Alcohol swabs for the vial cap and the skin site
• A sealable container for used needles

A note on dose magnitude: triptorelin is a highly potent peptide, with relevant amounts in the tenths-of-a-milligram range. That makes clean reconstitution and accurate reading on the insulin syringe especially important.

The powder is dissolved with bacteriostatic water. How much water you use determines the concentration and therefore how many units you later draw on the insulin syringe for your dose. Because triptorelin is often worked with in very small amounts, more solvent tends to make sense so the unit count you have to read off does not become tiny.

You can use the calculator above for exactly this: pick the vial size and water amount, and you immediately see the concentration and the units per dose.

In research discussion, triptorelin is usually injected subcutaneously into the fatty tissue under the skin (the approved depot products, by contrast, are intramuscular - a different, long-acting format). Typical subcutaneous sites are the abdomen (avoiding the area right around the navel), the front of the thigh, or the back of the upper arm.

• Clean the skin site with an alcohol swab and let it dry
• Pinch up a small fold of skin
• Insert the needle at a 45 to 90 degree angle
• Inject slowly, wait briefly, withdraw the needle
• Put the needle straight into the sharps container

Rotate the injection site every time.

The evidence base for triptorelin is extensive because it is an established drug:

• Prostate cancer: In a randomized trial, the triptorelin depot lowered and held testosterone at castration levels just as reliably as the comparator leuprolide, with a slightly slower onset (BJU International, 2003).
• Deep suppression: A pooled analysis of 920 patients showed that the depot formats pushed testosterone below even very low thresholds in the large majority (Advances in Therapy, 2016).
• Acute push: In delayed puberty, a single dose of triptorelin was used as a stimulation test - here the acute LH/FSH/testosterone rise is clearly measurable, the flare counterpart to chronic suppression (Turkish Journal of Pediatrics, 2001).
• Endometriosis: A review summarizes mechanism, pharmacokinetics and clinical data and describes how the hormone reduction triggered by continuous dosing was studied in the research context (Expert Opinion on Pharmacotherapy, 2014).

Important: all of this data comes from clearly defined medical indications under controlled conditions. Transferring it to other usage ideas is not backed by corresponding studies.

Because triptorelin intervenes directly in the hormone axis, the reported effects are mainly hormonal. Known from clinical data and the label:

• Flare phase: The initial testosterone/estradiol rise can temporarily amplify hormone-dependent symptoms. In prostate cancer use, that is precisely a documented risk (tumor flare).
• Suppression effects: With continuous dosing, the typical consequences of lowered sex hormone levels appear - reported among others are hot flashes, libido changes, and mood and energy swings.
• Metabolic: The label notes possible metabolic changes with longer GnRH agonist use (e.g. blood sugar, blood lipids).
• Local: Injection site reactions, as with any injection.

Intervening in the hormone axis is not a trivial band-aid topic. Anyone experimenting here should be aware of how deep the intervention runs.

Store the unreconstituted powder cool and dark. Once dissolved, the solution goes into the fridge (2 to 8 degrees) and keeps there for many weeks. The bacteriostatic water brings a preservative that keeps the dissolved form stable longer. Because of the small working amounts, it is worth labeling the vial cleanly (date, concentration) so nothing gets mixed up the next time you draw.